1-6 of 6
Erika Hamilton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from EMBER-2 Study.

Patrick Neven, Nicole Stahl, Maria Vidal, Miguel Martín, Peter A. Kaufman, Nadia Harbeck, Kelly K. Hunt, Stacey Carter, Francois-Clement Bidard, Peter A. Fasching, Philippe Aftimos, Duncan Wheatley, Erika Hamilton, Rebecca Aft, Swati Kulkarni, Peter Schmid, Manali Bhave, Roohi Ismail-Khan, Claudia Karacsonyi, Shawn T. Estrem, Bastien Nguyen, Umut Ozbek, Eunice Yuen, Vanessa Rodrik-Outmezguine, Eva Ciruelos
Journal: Clinical Cancer Research
Clin Cancer Res (2024)
https://doi.org/10.1158/1078-0432.CCR-24-2113
Published: 08 October 2024
View article titled, A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from EMBER-2 Study.
Open the PDF for A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from EMBER-2 Study. in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies

Sarina Piha-Paul, Shane A. Olwill, Erika Hamilton, Anthony Tolcher, Paula Pohlmann, Stephen V. Liu, Cornelia Wurzenberger, Laura-Carolin Hasenkamp, Eva-Maria Hansbauer, Rachna Shroff, Sara Hurvitz, Anuradha Krishnamurthy, Amita Patnaik, Noah Hahn, Raman Kumar, Manuela Duerr, Markus Zettl, Kayti Aviano, Louis Matis, Ingmar Bruns, Geoffrey Ku
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF11.
https://doi.org/10.1158/1078-0432.CCR-24-1552
Published: 26 September 2024
View article titled, A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Open the PDF for A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer

Sara M. Tolaney, Young-Hyuck Im, Emiliano Calvo, Yen-Shen Lu, Erika Hamilton, Andres Forero-Torres, Thomas Bachelot, Michela Maur, Angelica Fasolo, Ralph Tiedt, Lisa Nardi, Uz Stammberger, Ahmed M. Abdelhady, Shiling Ruan, Soo Chin Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 418–428.
https://doi.org/10.1158/1078-0432.CCR-20-0645
Published: 19 January 2021
View article titled, Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR<sup>+</sup> Advanced Breast Cancer
Open the PDF for Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR<sup>+</sup> Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial

Costanza Paoletti, Gaia Schiavon, Emily M. Dolce, Elizabeth P. Darga, T. Hedley Carr, Joseph Geradts, Matthias Hoch, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Shethah Morgan, Parul Patel, Vicky Rowlands, Nitharsan Sathiyayogan, Kimberly Aung, Erika Hamilton, Manish Patel, Anne Armstrong, Komal Jhaveri, Seock-Ah Im, Nadia Iqbal, Fouziah Butt, Caroline Dive, Elizabeth A. Harrington, J. Carl Barrett, Richard Baird, Daniel F. Hayes
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (23): 5860–5872.
https://doi.org/10.1158/1078-0432.CCR-18-1569
Published: 03 December 2018
View article titled, Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial
Open the PDF for Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial in another window
Includes: Supplementary data
Journal Articles

αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain

Dmitry Malin, Elena Strekalova, Vladimir Petrovic, Allison M. Deal, Abraham Al Ahmad, Barbara Adamo, C. Ryan Miller, Andrey Ugolkov, Chad Livasy, Karen Fritchie, Erika Hamilton, Kimberly Blackwell, Joseph Geradts, Matt Ewend, Lisa Carey, Eric V. Shusta, Carey K. Anders, Vincent L. Cryns
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (1): 56–67.
https://doi.org/10.1158/1078-0432.CCR-13-1255
Published: 05 January 2014
View article titled, αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain
Open the PDF for αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing

Christina I. Herold, Vijaya Chadaram, Bercedis L. Peterson, P. Kelly Marcom, Judith Hopkins, Gretchen G. Kimmick, Justin Favaro, Erika Hamilton, Renee A. Welch, Sarah Bacus, Kimberly L. Blackwell
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (18): 6061–6070.
https://doi.org/10.1158/1078-0432.CCR-11-1071
Published: 14 September 2011
View article titled, Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing
Open the PDF for Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing in another window
Includes: Supplementary data